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MEETING REPORT
CRC-BACR-AICR International Workshop
Melanogenesis: its Chemistry as a Therapeutic Strategy in Melanoma
Holly Royde Conference Centre, Manchester, UK, 17-20 March 1991
Organisers: Professor D.G. Harnden andDr E.J. Land (Paterson Institutefor Cancer Research, Manchester), Professor P.A.
Riley (University College and Middlesex School ofMedicine, London), Dr N. Thatcher (Christie Hospital, Manchester) and
Professor T.G. Truscott (University ofKeele).
The unique biochemical characteristic of melanocytes is the
propensity to produce melanin. The meeting was convened
specifically to examine recent advances in knowledge of
melanogenesis and the possibility that there might be some
way of exploiting the melanin-forming property of malignant
melanocytes as a means of treating melanoma. An improved
understanding of the chemistry of melanogenesis might lead
to the ability to manipulate such chemistry which could lead
to a treatment of melanoma based on subverting the chemis-
try of melanogenesis.
Melanoma and melanogenesis
The problem of melanoma was put in perspective by Profes-
sor Rona MacKie (Glasgow, UK) who discussed the epidem-
iology and pathogenesis of melanoma and emphasised the
importance of early detection, with the prognosis worsening
rapidly for increasingly thick lesions due to disseminated
disease. Epidemiological and case-controlled studies strongly
implicate ultra-violet radiation as a major aetiological factor
in cutaneous melanoma. Those at greatest risk appear to be
white-skinned subjects who have an indoor occupation but
who indulge in intense sun exposure for short periods of
time, e.g. on vacation. Additional risk factors include fair
complexion and large numbers of benign melanocytic naevi.
The classical Raper-Mason scheme for melanogenesis pos-
tulates a pathway involving, successively, tyrosine, dopa,
dopaquinone, dopachrome, dihydroxyindoles, indolequinones
.... leading to eumelanin, or phaeomelanin with the added
involvement of cysteine. Enzymes are essential to some reac-
tions in this process. Dr F. Solano (Murcia, Spain) described
how the regulation of mammalian eumelanogenesis is mainly
carried out not only by the well-known enzyme tyrosinase,
but also by the more recently discovered enzyme dopachrome
tautomerase. This enzyme is able to catalyze dopachrome
tautomerisation into 5,6-dihydroxyindole-2-carboxylic acid
(DHICA), thus preventing dopachrome decarboxylation tak-
ing place in the spontaneous rearrangement of dopachrome
into 5,6-dihydroxyindole (DHI) at neutral pH. As o-diph-
enols, both DHI and DHICA are possible substrates of
tyrosinase leading to the corresponding o-quinones. The
relative concentrations of these dihydroxyindoles, and hence
their o-quinones and the composition of the resulting eume-
lanin polymer, depends crucially upon the activity of both
enzymes. This controlled polymerisation may be a natural
mechanism to protect melanocytes against the known cyto-
toxicity of the decarboxylated indoles, which are more reac-
tive than their 2-carboxylated counterparts.
The possibility that peroxidase could also be involved in
later stages of the biosynthesis of eumelanins was discussed
by Professor G. Prota (Naples, Italy). Although peroxidase
cannot convert the monophenol, tyrosine, to the diphenol,
dopa, and hence lead to melanin, evidence was presented
showing that peroxidase is much more effective than tyro-
sinase in catalysing the oxidative conversion of DHI and
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DHICA to melanin pigments.
The stimulation oftyrosinase in melanoma cells by adreno-
ceptor agonists and by catecholic compounds was described
by Professor H. Rorsman (Lund, Sweden), the aim being to
try to develop ways of influencing the metabolism of cate-
chols. An increase in tyrosinase activity could thus lead to
the enhanced production of cytotoxic quinones. The stimula-
ting and cytotoxic effects of isoprenaline, theophylline, ter-
butaline and DOPAC on IGRI melanoma cells was discussed
in terms of their abilities to penetrate the cells, modify cell
proliferation and generate active oxygen species, including
H202. Active oxygen species appear to increase tyrosinase
activity in IGRI cells. Moreover, both the activation of
tyrosinase and the cytotoxic effects of catechols were found
to be eliminated by catalase.
The melanocytes of normal humans and melanoma
patients also contain the enzyme catechol-O-methyl trans-
ferase (COMT). This enzyme methylates the indolic melanin
precursors DHI and DHICA. Dr S. Pavel (Amsterdam, The
Netherlands) described the detection of such indoles in media
from human melanoma cell cultures. Most of these possess a
methoxy group in positions 5 or 6 which prevents their
oxidation to simple o-quinones. The methylation, which can
be considered as a protective mechanism in melanocytes
against intrinsically generated toxic o-hydroxy products, is
accomplished by intracellularly localised COMT.
Chemistry ofmelanogenesis
Several contributions dealt with detailed aspects of the chem-
istry of early stages in melanogenesis and related processes.
An overview of quinone reactivity with respect to melanin
formation was provided by Dr J.M. Bruce (Manchester,
UK). Although much of the chemistry of the melanogenesis
pathway up to the dihydroxyindoles DHI and DHICA is
fairly well understood, the subsequent stages, even those
leading to species with comparatively low molecular weight,
are not. The problem is compounded by the complexity of
the oxidation of DHI (and DHICA), which can, in principle,
lead not only to the corresponding ortho-quinone, but also to
both a quinone-imine and a quinone-methide, all three of
which may be in tautomeric equilibrium. Homo- and hetero-
coupling reactions involving one or more of these tautomers,
leading in the first place to a multiplicity of isomeric dimers,
could be important in the polymerisation ultimately resulting
in melanin.
Quinones and quinone-methides are also involved in the
molecular mechanisms for cuticular sclerotisation as des-
cribed by Professor M. Sugumaran (Boston, USA). The
exoskeleton of insects and other anthropods are hardened to
protect their soft bodies by a process called sclerotisation.
During hardening, soluble structural proteins and chitin
fibres are rendered insoluble by reaction with reactive species
derived from enzymatic activation by catecholamines, such as
N-acetyldopamine and N-3-alanyldopamine. Based on the
reactive species formed, two different mechanisms have been
identified to account for sclerotisation reactions. They are
quinone tanning and quinone-methide sclerotisation. Al-
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though initially these two mechanisms were considered to be
independent of each other, the recent discovery of two new
enzymes, quinone isomerase and quinone methide isomerase,
led to a unification of these mechanisms.
The initial steps involved in sclerotisation closely resemble
the initial reactions observed during melanisation. Both pro-
cesses involve the initial enzymic oxidation of catechols to
quinones, and quinone tautomerisation to quinone methides.
The introduction of a double bond into the side-chain and
the oxidation of the side-chain desaturated catecholamine
parallels the aromatisation of dopachrome to dihydroxyin-
dole, and the oxidation of dihydroxyindole to the correspond-
ing quinone.
Details of the chemistry of the transition: dopachrome
dihydroxyindole were described by Professor H. Wyler (Lau-
sanne, Switzerland). Four protonated forms of dopachrome
were identified, the 6-OH group deprotonating with a pK of
0.8, the carboxy group with a pK of 3.1 and the nitrogen
with a pK of 9.1. At neutral pH, the only product of
dopachrome decay is dihydroxyindole, whereas at high pH
(> 10) it is exclusively the anion of dihydroxyindole-2-car-
boxylic acid.
The maturity of the technique of pulse radiolysis is such
that one can now be confident enough to tackle problems as
complex as the process of melanogenesis. Although one-
electron oxidation of DHI and DHICA is not thought to be
a part of the melanogenic pathway, the rapid disproportiona-
tion of such radicals is an excellent means of preparing high
concentrations of the subsequent metastable intermediates,
e.g. indolequinones, which are thought to be important com-
ponents of the melanogenic pathway. Dr P. O'Neill (Chilton,
UK) described the one-electron oxidation of a series of
hydroxy- and methoxy-indoles using pulse radiolysis. One-
electron oxidation of dihydroxyindole in the pH range 5-10
yields the corresponding oxygen-centred indole semiquinone
radical (pK 6.8). With hydroxylated monomethoxyindoles,
the corresponding methoxyindoloxyl radical is formed. Fur-
ther methylation of the hydroxy substituents, as in dimeth-
oxyindole, results in the stabilisation of the corresponding
cation which, depending on the pH, deprotonates at N(l) to
yield the nitrogen-centred indolyl radical, with a pK of 6.0.
With the exception of dihydroxyindole, the radicals were
all found to decay bimolecularly to yield semi-permanent
products which eventually decayed unimolecularly. In the
case of dihydroxyindole, using very low pulse doses the
radical was found to decay unimolecularly. The latter decay
was assigned to a reaction of the radical with the parent
dihydroxyindole, rate constant - 106 M-i s'-. This could be
a component of the route for melanin polymerisation.
Professor T.G. Truscott (Keele, UK) described a closely
similar study of the species resulting from pulse radiolytic
one-electron oxidation of dihydroxyindoles and their meth-
oxylated metabolites. Whereas there was good agreement
with the results reported by the previous speaker on the
initially formed one-electron oxidised radicals, differences
were apparent in the nature of the reactions of some of the
radicals and subsequent metastable intermediates. A possible
scheme for polymerisation to melanin was proposed involv-
ing a reaction of a quinone-methide with water to produce a
trihydroxyindole, which may itself then react successively
with the methide to produce dimers, then trimers .... etc.
Professor B. Kalyanaraman (Milwaukee, USA) described
the application of the technique of electron spin resonance
spectroscopy to the identification and characterisation of free
radicals derived from melanin precursors. Complexed with
diamagnetic ions, especially Mg2' and Zn2+, catechol(amine)
semiquinones live I04 times as long as in the absence of the
metal, allowing their protonation-deprotonation reactions to
be readily studied. The addition reactions of quinones with
nucleophiles e.g. amino acids (proline and methionine), pep-
tides and proteins were also studied via the radicals derived
from such adducts.
Mechanisms associated with melanocytotoxic drugs
It was the discovery some 20 yeass ago that tyrosinase is
capable of oxidising substrates that are structural analogues
of tyrosine which suggested the possibility of using the
melanogenic pathway as a targeting strategy for melanoma
chemotherapy. Professor P.A. Riley (London, UK) described
a series of investigations on the mechanism of action of
substituted phenols of which the lead compound is the well-
known depigmenting agent 4-hydroxyanisole (4HA) which
is oxidised to the corresponding orthoquinone. The mechan-
ism of the cytotoxicity of the orthoquinone probably depends
predominantly on the formation of adducts with important
cellular thiol-containing proteins. The possibility that
the action depends on the generation of active oxygen species
by redox cycling has been excluded and there is little
evidence that semiquinones are involved in the toxic process
(see below). 4HA also exhibits direct toxic actions, including
inhibition of ribonucleotide reductase, inhibition of mito-
chondrial electron transport, and other effects on cell phy-
siology. Separation of these direct actions from the
tyrosinase-dependent cytotoxicity would serve to amplify the
therapeutic index against melanogenic cells, and the results of
tests on a series of derivatives of 4HA including a range of
oxy-ethers and thio-ethers ofdiffering chain length were pres-
ented. In discussion, Dr K. Schwabe (Berlin, Germany)
reported that his group had synthesised over 100 analogues
of 4HA and shown that the propyl oxy-ethers were therapeu-
tically effective against tumour volume in melanoma-bearing
animals, but had shown no effect on survival of the animals
employed in these tests.
The results of studies on the mechanism of cytotoxicity of
4HA and analogues were described by Dr E.J. Land (Man-
chester, UK). Using pulse radiolysis, semiquinones were
generated from the corresponding hydroquinones chemically
synthesised by Mr C.J. Cooksey. The semiquinones neither
reacted with oxygen nor with trans-butanoic acid, a water-
soluble model for unsaturated fatty acids. Consequently, it
appears unlikely that redox cycling or the initiation of lipid
peroxidation via semiquinones comprise the cytotoxic mech-
anism. The 3,4-quinones which form rapidly by dispropor-
tionation of the corresponding semiquinone were found to
react rapidly with several thiols and with ascorbic acid.
Nucleophilic addition of protein thiols to the quinone is thus
a more probable mediator of cytotoxicity. 4-(n-propoxy)
phenol, which possesses five times the in vitro tyrosinase-
dependent cytotoxicity towards rat cells compared with 4HA,
was found to behave almost identically as far as the reac-
tivity of semiquinones was concerned.
A closely similar approach to targeted cytotoxicity was
described by Professor K. Jimbow (Edmonton, Canada) who
showed that 4-S-cysteaminylphenol and some analogues are
selectively incorporated into murine melanoma tissue and
into actively melanising hair follicles with selective destruc-
tion of melanocytes resulting in depigmentation of black hair
follicles in mice, N-acetyl-4-S-cysteaminyl phenol being the
most potent inducer of selective destruction of follicular
melanocytes. This compound may prove to be a useful anti-
tumour agent judged by the data on subcutaneously inocu-
lated B16 FI0 melanoma cells in mice.
Dr P.G. Parsons (Queensland, Australia) reported that
despite many promising in vitro demonstrations of antimela-
noma activity by redox active agents such as catechols, and
by drugs such as buthionine sulphoximine which depress
cellular defences against oxygen radicals, there remain many
problems regarding the successful application of this app-
roach to melanomas in vivo. It may be possible to overcome
the lack of potency and selectivity of such agents by using
combinations of drugs. Such combination therapy, together
with measures for minimising mutation rates, may also com-
bat phenotypic instability leading to the development of drug
resistance.
Dr B.S. Larsson (Uppsala, Sweden) described an approach
towards the therapy of melanoma using aminothiol com-
pounds which are selectively incorporated into newly syn-
thesised melanin by reacting with orthoquinones generated
during melanogenesis. Various compounds of this class, in-
cluding thiourea and 2-thiouracil, have been shown by auto-
radiography to be specifically taken up into melanising tissue
including murine melanoma. Radioiodinated 5-iodo-2-uracil
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studies on treatment with 35S-thiouracil have been carried out
on melanoma-bearing mice. However, the radiation doses
required for substantial effects using this radionuclide are
extremely high, making therapeutic clinical application hazar-
dous. As an alternative, boron neutron capture therapy has
been attempted, using boronated thioureas which are selec-
tively incorporated into newly-synthesised melanin, and the
'0B can then be activated to undergo nuclear fission by
irradiation of tumours with thermal neutrons from an exter-
nal source.
Dr A.J. Winder (Oxford, UK) reported on the effects of
L-tyrosine phosphate and cytochalasin D on induction of
pigmentation in cells, with a view to the possibility
of developing differentiation therapy for melanoma. Both
agents produced a small increase in the amount of tyrosinase
messenger RNA, although the amount observed was
insufficient to account for the increase in enzyme activity.
The relationship between abnormal melanosome structure
and cytotoxic phenomena was discussed by Dr J. Borovansky
(Prague, Czechoslovakia). Electron microscope investigations
have confirmed the presence of abnormal and incomplete
melanosomes in human melanomas from epidermal and
mucosal sites, in melanoma metastases and in the B16 mouse
melanoma. For example, 90% of melanosomes in cutaneous
melanomas had membrane defects. Evidence that this leads
to significant leakage of reactive melanin precursors was
furnished by raised free radical-mediated lipid peroxidation
in the liver of B16 melanoma-bearing mice.
Melanoma and photobiology
The available information strongly suggests that excessive
exposure to sunlight, in particular its ultraviolet radiation B
(UVB) component, is a major factor in the development of
melanoma. With ozone depletion, sunlight will become en-
riched in UVB, thereby likely resulting in increased risk of
melanoma, unless behavioural changes are forthcoming in
susceptible populations. The current generation of children
and adolescents are the first to have been exposed at the
sensitive age to this UVB-enriched environment, and these
are likely to be the first cohorts to show increases in
melanoma due to ozone depletion.
Melanin itself is sensitive to light and oxygen, and Profes-
sor T. Sarna (Krakow, Poland) discussed the photoactivation
of melanin and the possible generation of cytotoxic products
resulting from it. Direct photo-oxidation of melanin was
accompanied by oxygen consumption and the production of
hydrogen peroxide. This process was shown to be strongly
wavelength- and pH-dependent and was also influenced by
the presence of metal ions. Photo-oxidation of melanin in the
presence of photosensitisers was also reported, and the possi-
bility ofcovalent binding of photosensitisers to melanin as an
approach to photodynamic therapy was discussed. Dr A.R.
Young (London, UK) discussed the apparently paradoxical
photoprotection of skin to UV-induced damage by prior
exposure to photosensitisers such as psoralens. Tans induced
by 5-methoxypsoralen (5-MOP) contained in a UVB sun-
screen with solar stimulating radiation (SSR) were found to
reduce unscheduled DNA synthesis following minimal ery-
thema doses of SSR. Despite the fact that 5-MOP is a weak
photocarcinogen, judicious use of 5-MOP-containing sun-
screens may offer benefits with regard to protection against
various forms of light-induced skin cancer which could
outweigh the risk involved. This may be of importance in
protecting future generations from the risk of developing
malignant melanoma.
Melanoma in the clinic
To round off the workshop, Dr N. Thatcher (Manchester,
UK) gave an overview of current clinical treatments for
melanoma. Beginning with the slogan 'If it's small cut it out',
he noted that perhaps the major obstruction towards improv-
ing the treatment of melanoma is pessimism.
The major current treatments for malignant melanoma are
surgery, radiotherapy, adjuvant treatment - so far disappoin-
ting and systemic approaches where metastases are present.
The Breslow thickness accurately predicts the prognosis -
lesions of 0.75 mm or less giving rise to a metastasis rate of
1%, whereas lesions of 3 mm or more are associated with a
metastasis rate of 84%. The Breslow thickness would then be
a reasonable basis on which to conduct adjuvant therapy
after treatment of the primary lesion and before systemic
metastases have become apparent. Surgery may also be em-
ployed in the treatment of metastatic melanoma of the brain,
lung, G.I. tract and superficial lesions in carefully selected
patients. Palliative radiotherapy can also be of use, partic-
ularly in the treatment of superficial lesions and bone metas-
tases.
The response to systemic therapy (hormones, chemother-
apy) is always higher in skin, lymph nodes and favourable
sites in soft tissue rather than in visceral organs - liver, bone,
etc. Tamoxifen, (trans-2-[4-(1;2-diphenyl-l-butenyl)phenoxy]-
N,N-dimethylethylamine), is of great value in breast cancer,
and has been used to treat melanoma following the identi-
fication in some patients of oestrogen receptors on the
melanoma cell. Occasional reports of responses in post-meno-
pausal women have been published although the speaker
could not confirm this activity. DTIC(5-(3,3-dimethyl-l-tria-
zino)imidazole-4-carboxamide) has provided the most consis-
tent tumour response rate of about 15%. Other agents in
combination regimes also have been tried, including recently
cis-platin, with response rates, in some instances, of 40% or
more. The use of high dose melphalan (4-[bis(2-chloro-
ethyl)amino]-phenylalanine), DTIC and other agents with
autologous bone marrow rescue has not improved the sur-
vival although response rate have been increased to above
50% in some studies.
New drugs such as detrorubicin (the glyoxylic acid ester of
the anthracycline adriamycin), dibromodulcitol (1,6-dibromo-
1,6-dideoxy-D-galactitol), taxol (the tubulin stabilising com-
pound), and the nitrosamino-phosphonic ester fotemustine
have shown some activity, particularly the latter even in
cerebral metastases.
One important new avenue of treatment involves immuno-
therapy with interferons and other biological response
modifiers such as interleukin-2. These agents also have been
used singlularly or in combination with each other, with
monoclonal antibodies and cytotoxic agents such as DTIC,
cis-platin and flavone acetic acid. Despite the promise of this
new treatment, objective tumour responses are still of the
order of 20%.
It is clear that the efficacy of current treatments for metas-
tasising melanoma is highly unsatisfactory and that new
treatments are urgently needed. Future methods may include
hormone therapy, new biological agents, gene therapy and
the use of pro-drugs activated by tyrosinase, towards which
approach it is hoped this Workshop will have contributed.
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